IMPORTANCE Hemophagocytic lymphohistiocytosis (HLH) has been reported as a serious complication of cutaneous T-cell lymphoma (CTCL). Despite available diagnostic guidelines, it remains a diagnostic and therapeutic challenge in this patient population.
H emophagocytic lymphohistiocytosis (HLH) is an aggressive, frequently fatal syndrome of excessive immune activation. 1, 2 According to the commonly used HLH-2004 trial criteria, the diagnosis of HLH requires meeting at least 5 of 8 criteria. 3 More recently, Fardet and colleagues 4 proposed the HScore, which incorporates similar criteria to estimate the risk of having secondary HLH. Despite these tools, HLH remains a diagnostic challenge. 2, 4 Up to 27% of cases of HLH are secondary to malignant tumors, particularly T-cell and natural killer/T-cell lymphomas. 5, 6 In this report, we describe one of the largest series of patients diagnosed with HLH associated with cutaneous T-cell lymphoma (CTCL) reported to date.
Methods
We identified 7 patients with CTCL who developed HLH from January 1, 2014, through December 31, 2017. Clinical and laboratory data used in the diagnosis and management of CTCL and HLH were recorded and reviewed. An HScore value that reflected the probability of HLH was calculated for each patient. 4 Descriptive statistics of quantitative variables were calculated. For part of the sample, a waiver of consent was allowed; 3 patients were included with written consent. The study was approved by the Northwestern University Institutional Review Board.
Results
Seven patients with CTCL associated with HLH (4 men and 3 women; median age, 50 years; range, 34-77 years) were identified ( Table 1 ). All had cytotoxic CTCL variants: 3 with primary cutaneous γΔ T-cell lymphoma, 1 with intravascular γΔ T-cell lymphoma presenting with skin lesions, 1 with subcutaneous panniculitis-like T-cell lymphoma, 1 with double CD4/CD8-negative CTCL unspecified, and 1 with Epstein-Barr virus-positive natural killer/T-cell lymphoma with the γΔ phenotype. Only 2 patients had hemophagocytosis apparent on skin biopsy specimens ( Table 2) . Median time from presentation to initiation of treatment for HLH was 1 month (range, 0.3-2.5 months). Two patients received etoposide monotherapy, 3 received polychemotherapy regimens, and 3 received allogeneic hematopoietic stem cell transplants (HSCTs). Four patients died of disease, with a median time from diagnosis of HLH to death of 0.2 months. Three patients, all of whom received allogeneic HSCTs, were alive without disease, with a median follow-up of 33.2 months (range, 13.1-45.1 months).
Discussion
Considering the rarity of CTCL and HLH, this is one of the largest case series of patients presenting with both conditions. Our results suggest that of the different CTCL subtypes, cytotoxic variants, especially cases that involve subcutaneous tissue, are most commonly associated with HLH. In addition, when HLH is associated with cytotoxic CTCL, it frequently manifests early in the natural course of the malignant tumor and within 1 year of diagnosis. Finally, cytotoxic lymphomas with HLH tend to present with extensive necrosis and hemorrhage and are often accompanied by a mixed inflammatory and granulomatous reaction that may jeopardize the lymphoma diagnosis and incorporate conditions such as sarcoidosis into the differential diagnosis.
The possible association between HLH and cytotoxic CTCL may relate to the pathogenesis of HLH, which is believed to involve failure of cytotoxic lymphocytes to remove activated histiocytes. 1 Of the different subtypes of cytotoxic CTCL, primary cutaneous γΔ T-cell lymphoma and subcutaneous panniculitislike T-cell lymphoma were most commonly observed.
Cytotoxic CTCLs are frequently difficult to diagnose because their unusual clinical presentation often clinically and pathologically resembles infectious, autoimmune, or vasculitic conditions. In addition, tumor cells may be difficult to identify because the lymphoma is deep dermal or subcutaneous
Key Points
Question What are the characteristics of patients with cutaneous T-cell lymphoma and hemophagocytic lymphohistiocytosis with respect to cutaneous T-cell lymphoma subtype, treatment received, and outcome?
Findings In this case series of 7 patients, cytotoxic cutaneous T-cell lymphoma subtypes that involve the deep dermis and subcutaneous tissue were most commonly associated with hemophagocytic lymphohistiocytosis. Patients receiving allogeneic stem cell transplants had the best outcomes.
Meaning Hemophagocytic lymphohistiocytosis is a rare, life-threatening complication of cutaneous T-cell lymphoma that is mostly associated with cytotoxic cutaneous T-cell lymphoma involving the deep dermis and subcutaneous tissue; awareness that it may mimic a granulomatous or infectious condition, resulting in delayed diagnosis and incorrect treatment, is critical. in a background of necrosis, hemorrhage, and mixed inflammation. The unexpected phenotype may further complicate diagnosis. All skin biopsy specimens in our cohort showed CTCL that involved the deep dermis or subcutaneous tissue. Moreover, the common constitutional symptoms of systemic malignant tumors may complicate the diagnosis of HLH when the 2 conditions present simultaneously. Because initial symptoms are nonspecific (eg, fever, malaise, and fatigue), they can be mistaken for the constitutional symptoms of cancer and inflammatory or autoimmune disorders or infection. Misdiagnosing HLH as an inflammatory or autoimmune disorder in a patient with CTCL, as seen in 2 of our patients who were initially diagnosed as having sarcoidosis, can lead to inappropriate and delayed treatment, resulting in disease progression. Therefore, high suspicion by the clinician, along with a comprehensive workup and fast intervention, is warranted. Diagnostic criteria for secondary HLH may also require comprehensive review. At the time of diagnosis, most of our patients had a vhigh probability of HLH calculated by HScore. 4 Unlike the HLH-2004 trial criteria, which are mostly designed and used for primary HLH in children, the HScore was designed based on patients with secondary HLH of various origins; because it includes c At presentation (before patient was considered to meet full diagnosis of HLH), patient 1 had an HScore of 89 (76.0% probability of having HLH). d Not all laboratory data were reported, which affected the number of HLH criteria met and prevented calculation of an HScore. The histologic finding of hemophagocytosis is neither sensitive nor specific for the diagnosis of HLH. 4, 7, 8 Bone marrow biopsies are rarely performed in CTCL, and skin biopsy specimens often fail to show hemophagocytosis. Thus, cytophagocytosis in the skin of patients with CTCL has low sensitivity and/or specificity for HLH. Secondary infections could trigger HLH in these patients because of disease-related and/or iatrogenic immunosuppression. In addition, HLH symptoms may resemble sepsis, which must be excluded before initiating therapy with high-dose corticosteroids or cyclosporine.
Limitations
This study is a retrospective medical record review of a small cohort. The rarity of HLH and CTCL ideally involves multicenter, prospective collaborations.
Conclusions
Given the rarity of HLH and CTCL, no established treatment guidelines exist for patients with both conditions. Although cyclosporine is generally contraindicated in most CTCL types, it has been successful in some cases of HLH and CTCL and may be a viable option in this context. [9] [10] [11] [12] [13] In our experience, cyclosporine helped to manage the initial HLH stage but was not successful as a long-term option for the malignant condition. Because controlling HLH and CTCL may require different therapies, treatment combinations may be required to achieve long-lasting responses. In our experience, allogeneic HSCT has been the most successful therapy for a long-lasting response. Allogeneic HSCT may repair germline defects of the innate immune system and simultaneously provide a graft vs lymphoma effect, which plays an important role in controlling T-cell lymphomas. 14 Largescale, prospective studies are needed to assess the long-term efficacy of allogeneic HSCT and to develop treatment guidelines for patients with HLH and CTCL.
